The Food and Drug Administration announced Friday it had officially declared an end to the nationwide shortage of Ozempic and Wegovy, medications used for diabetes and weight loss.The agency first ...

The U.S. Food and Drug Administration said Ozempic and Wegovy, the popular GLP-1 drugs for diabetes and weight loss, are no ...

CHICAGO — A shooting inside a car dealership on the city’s Southwest Side left two people injured on Thursday afternoon.

The semaglutide shortage has officially ended in the US—which means the GLP-1 drug industry is about to undergo massive ...

Maryland Attorney General Anthony G. Brown has joined forces with a 37-state coalition to urge the Food and Drug ...

The manufacturer of the weight loss jab Wegovy has been reprimanded for allegedly failing to disclose or accurately report payments to healthcare and patient organisations.

A new study adds to a growing body of evidence that semaglutide has benefits other than weight loss or controlling diabetes.

Cue the advent of Glucagon-like peptide 1 agonists (GLP-1s) such as Ozempic and Wegovy. First approved by the FDA in 2005 for type 2 diabetes, Ozempic showed incredible promise in not only ...

FRIDAY, Feb. 7, 2025 (HealthDay News) -- Add surgical tweaks to fix so-called "Ozempic face" to the list of top trending cosmetic procedures, as tallied by the American Academy of Facial Plastic ...

A drug for treating diabetes similar to popular weight-loss medicines such as Ozempic did not show any benefits for people with Parkinson’s disease, according to a new study. Researchers ...

GLP-1 agonist jabs, like Mounjaro and Wegovy, reduce people’s appetites. They can also slow down the digestive process. This helps patients to consume fewer calories and get rid of excess weight.

Ozempic and Wegovy has been prescribed to Yorkshire patients hundreds of times in the past year - and it's not for weightloss. According to data from the NHS' Open Prescribing service, semaglutide ...